These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25205728)

  • 1. Non-B HIV-1 subtypes in sub-Saharan Africa: impact of subtype on protease inhibitor efficacy.
    Naicker P; Sayed Y
    Biol Chem; 2014 Oct; 395(10):1151-61. PubMed ID: 25205728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibition in African subtypes of HIV-1.
    Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
    AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance in non-subtype B HIV-1.
    Kantor R; Katzenstein D
    J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth.
    Walker PR; Pybus OG; Rambaut A; Holmes EC
    Infect Genet Evol; 2005 Apr; 5(3):199-208. PubMed ID: 15737910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
    Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
    Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS care and treatment in sub-Saharan Africa.
    Kassaye SG; Katzenstein D
    AIDS Rev; 2003; 5(4):195-204. PubMed ID: 15011998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of HIV-1 subtype on the clinical response on HAART.
    Frater J
    J HIV Ther; 2002 Nov; 7(4):92-6. PubMed ID: 12733607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(3):302-10. PubMed ID: 20845636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India.
    Azam M; Malik A; Rizvi M; Rai A
    J Infect Dev Ctries; 2014 Jan; 8(1):79-85. PubMed ID: 24423716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Status of resistance of HIV-1 strains in Africa: what is the role of viral surveillance networks?].
    Grandadam M; Nicand E; Koeck JL; Caron M; Teyssou R
    Med Trop (Mars); 2002; 62(1):89-93. PubMed ID: 12038188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
    Bessong PO
    Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.